United Therapeutics CorporationUTHRNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Year-over-year research & development expense growth
Latest
17.89%
↓ 39% below average
Average (9y)
29.15%
Historical baseline
Range
High:230.43%
Low:-69.75%
CAGR
+37.0%
Consistent expansion
| Period | Value |
|---|---|
| 2024 | 17.89% |
| 2023 | 26.35% |
| 2022 | -40.21% |
| 2021 | 50.99% |
| 2020 | -69.75% |
| 2019 | 230.43% |
| 2018 | 35.26% |
| 2017 | 79.27% |
| 2016 | -39.78% |
| 2015 | 1.05% |